Key factors
sym | REXN |
exch | US |
MCap | 2028.65K |
Beta | 0.973 |
EPS | -4.83 |
Div date | 0000-00-00 |
Yesterday
sym | REXN |
exch | US |
close | 6.0 |
50 Day MA | 7.198 |
200 Day MA | 9.508 |
Target Price | 3.0 |
Market Cap Mln | 2.028 |
Share statistics
Shares Outstanding | 4483.2K |
Shares Float | 4010.14K |
Percent Institutions | 8.326 |
PercentInsiders | 0.222 |
SharesShort | 13595 |
Short Ratio | 0.05 |
Shares Short Prior Month | 2963.0 |
Short Percent | 0.079 |
Income
Revenue TTM | 1150.0K |
Revenue Per Share TTM | 0.282 |
EBITDA | -16.5M |
Diluted Eps TTM | -2.65 |
earning
Operating Margin TTM | -5.58 |
Earnings Share | -4.83 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2019-04-12 |
Last Split Factor | 1:12 |
business
Enterprise Value Ebitda | 0.021 |
Enterprise Value Revenue | 0.117 |
Book Value /share | 2.925 |
Price Book MRQ | 1.420 |
Price Sales TTM | 6.413 |
ReturnOnAssetsTTM | -0.33 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US7616403090 |
CIK | 1228627 |
Code | REXN |
CUSIP | 22003E100 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2023-12-12 |
is Delisted | 1 |
Delisted Date | 2020-11-06 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 5.0 |
IPODate | 2005-05-23 |
MostRecent Quarter | 2020-09-30 |
Contact
Name | Rexahn Pharmaceuticals Inc |
Address | 15245 Shady Grove Road, Rockville, MD, United States, 20850 |
Country Name | USA |
Phone | 240 268 5300 |
Web URL | www.rexahn.com |
Logo URL | /img/logos/US/REXN.png |
As of November 5, 2020, Rexahn Pharmaceuticals, Inc. was acquired by Ocuphire Pharma, Inc., in a reverse merger transaction. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.